{
  "actions": [
    {
      "acted_at": "2022-05-06",
      "action_code": "Intro-H",
      "references": [],
      "text": "Introduced in House",
      "type": "action"
    },
    {
      "acted_at": "2022-05-06",
      "action_code": "H11100",
      "committees": [
        "HSIF"
      ],
      "references": [],
      "status": "REFERRED",
      "text": "Referred to the House Committee on Energy and Commerce.",
      "type": "referral"
    },
    {
      "acted_at": "2022-05-09",
      "action_code": "",
      "committees": [
        "HSIF"
      ],
      "references": [],
      "text": "Referred to the Subcommittee on Health.",
      "type": "referral"
    },
    {
      "acted_at": "2022-05-11",
      "action_code": "",
      "committees": [
        "HSIF"
      ],
      "references": [],
      "text": "Subcommittee Consideration and Mark-up Session Held.",
      "type": "action"
    },
    {
      "acted_at": "2022-05-11",
      "action_code": "",
      "committees": [
        "HSIF"
      ],
      "references": [],
      "text": "Forwarded by Subcommittee to Full Committee (Amended) by the Yeas and Nays: 30 - 0 .",
      "type": "action"
    },
    {
      "acted_at": "2022-05-18",
      "action_code": "",
      "committees": [
        "HSIF"
      ],
      "references": [],
      "text": "Committee Consideration and Mark-up Session Held.",
      "type": "action"
    },
    {
      "acted_at": "2022-05-18",
      "action_code": "",
      "committees": [
        "HSIF"
      ],
      "references": [],
      "status": "REPORTED",
      "text": "Ordered to be Reported (Amended) by the Yeas and Nays: 55 - 0.",
      "type": "ordered-reported"
    },
    {
      "acted_at": "2022-06-07",
      "action_code": "H12200",
      "committees": [
        "HSIF"
      ],
      "references": [],
      "text": "Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 117-348.",
      "type": "action"
    },
    {
      "acted_at": "2022-06-07",
      "action_code": "H12410",
      "calendar": "Union",
      "number": "262",
      "references": [],
      "text": "Placed on the Union Calendar, Calendar No. 262.",
      "type": "calendar",
      "under": null
    },
    {
      "acted_at": "2022-06-07T18:17:55-04:00",
      "action_code": "H30300",
      "references": [],
      "text": "Mr. Pallone moved to suspend the rules and pass the bill, as amended.",
      "type": "action"
    },
    {
      "acted_at": "2022-06-07T18:18:16-04:00",
      "action_code": "H30000",
      "references": [
        {
          "reference": "CR H5298-5321",
          "type": "consideration"
        }
      ],
      "text": "Considered under suspension of the rules.",
      "type": "action"
    },
    {
      "acted_at": "2022-06-07T18:18:18-04:00",
      "action_code": "H8D000",
      "references": [],
      "text": "DEBATE - The House proceeded with forty minutes of debate on H.R. 7667.",
      "type": "action"
    },
    {
      "acted_at": "2022-06-07T18:38:20-04:00",
      "action_code": "H37220",
      "references": [],
      "text": "At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.",
      "type": "action"
    },
    {
      "acted_at": "2022-06-08T20:23:21-04:00",
      "action_code": "H30000",
      "references": [
        {
          "reference": "CR H5402-5403",
          "type": "consideration"
        }
      ],
      "text": "Considered as unfinished business.",
      "type": "action"
    },
    {
      "acted_at": "2022-06-08T20:31:13-04:00",
      "action_code": "H37300",
      "how": "roll",
      "references": [
        {
          "reference": "06/07/2022 CR H5298-5319",
          "type": "text"
        }
      ],
      "result": "pass",
      "roll": "254",
      "status": "PASS_OVER:HOUSE",
      "suspension": true,
      "text": "On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 392 - 28 (Roll no. 254).",
      "type": "vote",
      "vote_type": "vote",
      "where": "h"
    },
    {
      "acted_at": "2022-06-08T20:31:14-04:00",
      "action_code": "H38310",
      "references": [],
      "text": "Motion to reconsider laid on the table Agreed to without objection.",
      "type": "action"
    },
    {
      "acted_at": "2022-06-09",
      "action_code": "",
      "references": [],
      "text": "Received in the Senate.",
      "type": "action"
    }
  ],
  "amendments": [],
  "bill_id": "hr7667-117",
  "bill_type": "hr",
  "by_request": false,
  "committee_reports": [
    "H. Rept. 117-348"
  ],
  "committees": [
    {
      "activity": [
        "reporting",
        "markup",
        "referral"
      ],
      "committee": "House Energy and Commerce",
      "committee_id": "HSIF"
    },
    {
      "activity": [
        "reporting",
        "markup",
        "referral"
      ],
      "committee": "House Energy and Commerce",
      "committee_id": "HSIF",
      "subcommittee": "Subcommittee on Health",
      "subcommittee_id": "14"
    }
  ],
  "congress": "117",
  "cosponsors": [
    {
      "bioguide_id": "G000558",
      "district": "2",
      "name": "Guthrie, Brett",
      "original_cosponsor": true,
      "sponsored_at": "2022-05-06",
      "state": "KY",
      "title": "Rep.",
      "withdrawn_at": null
    },
    {
      "bioguide_id": "M001159",
      "district": "5",
      "name": "McMorris Rodgers, Cathy",
      "original_cosponsor": true,
      "sponsored_at": "2022-05-06",
      "state": "WA",
      "title": "Rep.",
      "withdrawn_at": null
    },
    {
      "bioguide_id": "P000034",
      "district": "6",
      "name": "Pallone, Frank, Jr.",
      "original_cosponsor": true,
      "sponsored_at": "2022-05-06",
      "state": "NJ",
      "title": "Rep.",
      "withdrawn_at": null
    }
  ],
  "enacted_as": null,
  "history": {
    "active": true,
    "active_at": "2022-05-11",
    "awaiting_signature": false,
    "enacted": false,
    "house_passage_result": "pass",
    "house_passage_result_at": "2022-06-08T20:31:13-04:00",
    "vetoed": false
  },
  "introduced_at": "2022-05-06",
  "number": "7667",
  "official_title": "To amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs, medical devices, generic drugs, and biosimilar biological products, and for other purposes.",
  "popular_title": null,
  "related_bills": [
    {
      "bill_id": "hr2565-117",
      "identified_by": "CRS",
      "reason": "related",
      "type": "bill"
    },
    {
      "bill_id": "hr6888-117",
      "identified_by": "CRS",
      "reason": "related",
      "type": "bill"
    },
    {
      "bill_id": "hr6980-117",
      "identified_by": "CRS",
      "reason": "related",
      "type": "bill"
    },
    {
      "bill_id": "hr7006-117",
      "identified_by": "CRS",
      "reason": "related",
      "type": "bill"
    },
    {
      "bill_id": "hr7032-117",
      "identified_by": "CRS",
      "reason": "related",
      "type": "bill"
    },
    {
      "bill_id": "hr7035-117",
      "identified_by": "CRS",
      "reason": "related",
      "type": "bill"
    },
    {
      "bill_id": "hr7084-117",
      "identified_by": "CRS",
      "reason": "related",
      "type": "bill"
    },
    {
      "bill_id": "hr7649-117",
      "identified_by": "CRS",
      "reason": "related",
      "type": "bill"
    },
    {
      "bill_id": "hr7658-117",
      "identified_by": "CRS",
      "reason": "related",
      "type": "bill"
    },
    {
      "bill_id": "s2952-117",
      "identified_by": "CRS",
      "reason": "related",
      "type": "bill"
    },
    {
      "bill_id": "s3983-117",
      "identified_by": "CRS",
      "reason": "related",
      "type": "bill"
    },
    {
      "bill_id": "s4152-117",
      "identified_by": "CRS",
      "reason": "related",
      "type": "bill"
    },
    {
      "bill_id": "s3478-117",
      "identified_by": "CRS",
      "reason": "related",
      "type": "bill"
    },
    {
      "bill_id": "hr6988-117",
      "identified_by": "CRS",
      "reason": "related",
      "type": "bill"
    },
    {
      "bill_id": "s4351-117",
      "identified_by": "CRS",
      "reason": "related",
      "type": "bill"
    },
    {
      "bill_id": "s4302-117",
      "identified_by": "CRS",
      "reason": "related",
      "type": "bill"
    },
    {
      "bill_id": "s4333-117",
      "identified_by": "CRS",
      "reason": "related",
      "type": "bill"
    },
    {
      "bill_id": "s4338-117",
      "identified_by": "CRS",
      "reason": "related",
      "type": "bill"
    },
    {
      "bill_id": "s4535-117",
      "identified_by": "CRS",
      "reason": "related",
      "type": "bill"
    },
    {
      "bill_id": "hr9297-117",
      "identified_by": "CRS",
      "reason": "related",
      "type": "bill"
    }
  ],
  "short_title": "Food and Drug Amendments of 2022",
  "sponsor": {
    "bioguide_id": "E000215",
    "district": "18",
    "name": "Eshoo, Anna G.",
    "state": "CA",
    "title": "Rep.",
    "type": "person"
  },
  "status": "PASS_OVER:HOUSE",
  "status_at": "2022-06-08T20:31:13-04:00",
  "subjects": [
    "Advanced technology and technological innovations",
    "Advisory bodies",
    "Animal protection and human-animal relationships",
    "Blood and blood diseases",
    "Business records",
    "Cardiovascular and respiratory health",
    "Child health",
    "Computer security and identity theft",
    "Congressional oversight",
    "Criminal investigation, prosecution, interrogation",
    "Department of Health and Human Services",
    "Drug safety, medical device, and laboratory regulation",
    "Emergency medical services and trauma care",
    "Employee hiring",
    "Evidence and witnesses",
    "Executive agency funding and structure",
    "Food and Drug Administration (FDA)",
    "Genetics",
    "Government employee pay, benefits, personnel management",
    "Government information and archives",
    "Government studies and investigations",
    "Health",
    "Health care coverage and access",
    "Health programs administration and funding",
    "Health technology, devices, supplies",
    "Industrial facilities",
    "Infectious and parasitic diseases",
    "Inflation and prices",
    "Licensing and registrations",
    "Manufacturing",
    "Marketing and advertising",
    "Medical research",
    "Minority health",
    "Musculoskeletal and skin diseases",
    "Organ and tissue donation and transplantation",
    "Performance measurement",
    "Photography and imaging",
    "Prescription drugs",
    "Product development and innovation",
    "Public participation and lobbying",
    "Public-private cooperation",
    "Radiation",
    "Research and development",
    "Small business",
    "User charges and fees"
  ],
  "subjects_top_term": "Health",
  "summary": {
    "as": "Passed House",
    "asOf": "2022-06-08",
    "date": "2022-06-25T00:31:45Z",
    "text": "Food and Drug Amendments of 2022\n\nThis bill reauthorizes Food and Drug Administration (FDA) user fee programs for certain drugs and devices, establishes requirements to increase diversity in clinical trials, and modifies requirements relating to the overall supply chain for drugs and devices.\n\nSpecifically, the bill reauthorizes through FY2027 the FDA user fee programs for prescription drugs, medical devices, generic drugs, and biosimilars.\n\nThe bill also requires the development of action plans and related reporting to increase the diversity of participants in clinical trials.\n\nIn addition, the bill requires the FDA to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why).\n\nThe bill also (1) establishes requirements and reauthorizes programs to support the development of specific categories of drugs and devices (e.g., pediatric drugs) and inspections of drug manufacturing facilities; and (2) establishes and revises requirements relating to the approval of drugs and devices, including requirements for postapproval studies and guidance about using real-world evidence to support drug and device applications."
  },
  "titles": [
    {
      "as": null,
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "Food and Drug Amendments of 2022",
      "type": "display"
    },
    {
      "as": "introduced",
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "Food and Drug Amendments of 2022",
      "type": "short"
    },
    {
      "as": "introduced",
      "is_for_portion": true,
      "textVersionCode": null,
      "title": "Biosimilar User Fee Amendments of 2022",
      "type": "short"
    },
    {
      "as": "introduced",
      "is_for_portion": true,
      "textVersionCode": null,
      "title": "Generic Drug User Fee Amendments of 2022",
      "type": "short"
    },
    {
      "as": "introduced",
      "is_for_portion": true,
      "textVersionCode": null,
      "title": "Medical Device User Fee Amendments of 2022",
      "type": "short"
    },
    {
      "as": "introduced",
      "is_for_portion": true,
      "textVersionCode": null,
      "title": "Prescription Drug User Fee Amendments of 2022",
      "type": "short"
    },
    {
      "as": "reported to house",
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "Food and Drug Amendments of 2022",
      "type": "short"
    },
    {
      "as": "reported to house",
      "is_for_portion": true,
      "textVersionCode": null,
      "title": "Biosimilar User Fee Amendments of 2022",
      "type": "short"
    },
    {
      "as": "reported to house",
      "is_for_portion": true,
      "textVersionCode": null,
      "title": "Generic Drug User Fee Amendments of 2022",
      "type": "short"
    },
    {
      "as": "reported to house",
      "is_for_portion": true,
      "textVersionCode": null,
      "title": "Medical Device User Fee Amendments of 2022",
      "type": "short"
    },
    {
      "as": "reported to house",
      "is_for_portion": true,
      "textVersionCode": null,
      "title": "Prescription Drug User Fee Amendments of 2022",
      "type": "short"
    },
    {
      "as": "passed house",
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "Food and Drug Amendments of 2022",
      "type": "short"
    },
    {
      "as": "passed house",
      "is_for_portion": true,
      "textVersionCode": null,
      "title": "Biosimilar User Fee Amendments of 2022",
      "type": "short"
    },
    {
      "as": "passed house",
      "is_for_portion": true,
      "textVersionCode": null,
      "title": "Generic Drug User Fee Amendments of 2022",
      "type": "short"
    },
    {
      "as": "passed house",
      "is_for_portion": true,
      "textVersionCode": null,
      "title": "Medical Device User Fee Amendments of 2022",
      "type": "short"
    },
    {
      "as": "passed house",
      "is_for_portion": true,
      "textVersionCode": null,
      "title": "Prescription Drug User Fee Amendments of 2022",
      "type": "short"
    },
    {
      "as": "introduced",
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "To amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs, medical devices, generic drugs, and biosimilar biological products, and for other purposes.",
      "type": "official"
    }
  ],
  "updated_at": "2023-12-05T10:26:21Z",
  "url": "https://www.govinfo.gov/bulkdata/BILLSTATUS/117/hr/BILLSTATUS-117hr7667.xml"
}